Radiotherapy-immunotherapy combinations - perspectives and challenges.

Area of Science:

• Oncology
• Immunology
• Radiation Oncology

Background:

• Radiotherapy (RT) traditionally targets cancer by inducing DNA damage in tumor cells.
• Emerging evidence shows RT modulates the tumor microenvironment and immune response.
• This has led to the development of immunoradiotherapy, combining RT with immunomodulators.

Purpose of the Study:

• To explore the potential of combining radiotherapy with immunomodulators for enhanced cancer treatment.
• To highlight the growing interest and rationale behind immunoradiotherapy.
• To identify key challenges and future directions in the field.

Main Methods:

• Review of preclinical and clinical data on RT combined with immunomodulators, including immune checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA4).
• Analysis of the synergistic potential of local RT to amplify systemic anti-tumor responses.
• Discussion of current challenges and future research needs.

Main Results:

• The combination of RT with immunomodulators, particularly immune checkpoint inhibitors, shows significant promise.
• Immunoradiotherapy leverages RT's ability to modulate the tumor microenvironment to boost systemic anti-tumor immunity.
• The abscopal effect exemplifies the potential for local RT to induce distant tumor regression.

Conclusions:

• Immunoradiotherapy represents a promising approach to cancer treatment by integrating RT with immunotherapy.
• Key challenges include identifying predictive biomarkers, optimizing treatment schedules, and overcoming resistance mechanisms.
• Further research and investment are crucial to fully realize the potential of immunoradiotherapy and address toxicity concerns.